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Today, laboratories are very much different than they were decades ago. They have improved 
instruments to work with, multiple off-site collection 
points, more competent personnel, a greater analyte 
panel and quality requirements for those analytes. 
Nevertheless, sample quality has to be assured along 
the total testing process (TTP) in order to guarantee 
reliable results to the patient. In routine coagulation, 
prothrombin time (PT), activated partial thromboplastin 
time (APTT), fibrinogen (Fbg) and D-dimer are 
the essential part of the test panel, for which new 
evidences about sample quality requirements have 
been presented in recent years.
 
What’s new about patient preparation?
To fast or not to fast is a much discussed topic in 
laboratory medicine these days (1). Apart from those 
discussions, we must take in consideration that refer-
ence intervals and biological variation data are derived 
from fasting individuals (2), and so patient test results 
should in theory be compared in the same manner.  
In hemostasis, the most recent evidence (3), have 
shown that a standardized morning light meal has no 
clinical significant influence on test results (PT, APTT, 
Fbg, AT, PC and PS) as compared with reference 
change value (RCV). Despite that, significant statistical 
lipemia interference was observed after one hour for 
several analytes (APTT, PT, AT and PC), even though 
it wasn’t detected by visual inspection. As laboratories 
have no control over what people eat in the morning, 
and the great majority of test requests also include 
other tests with fasting requirement, the wisest move 
is to instruct patients to fast.
In clinical settings such as emergency department 
or oral anticoagulant therapy (with blood collection 
after lunch), clearly lipemic samples are more prone 
to occur and leading to erroneous results (4). What 
to do in such occasions? To postpone the analysis 
and collect a novel sample later or in the fasting state 
is always the best option. Where this is not feasible, 
interference removal can be attempted, either by 
ultracentrifugation (5), dilution or extraction, each one 
having its drawbacks (4,6).  
What’s new about sample collection?
Phlebotomy is a highly variable procedure, because 
it depends on many factors such as the patient 
condition, the more or less controlled setting of 
execution (outpatient vs inpatient vs emergency 
departments), the skill of the healthcare professional, 
and the material choice (evacuated vs non-evacuated 
tubes; straight needle vs butterfly devices vs IV starts). 
One of the main questions frequently arising in 
the moment of phlebotomy is the tube order of draw. 
Currently, CLSI GP41-A6 - Procedures for the Collection 
of  Diagnostic Blood Specimens by Venipuncture (7), 
recommends that coagulation tubes should be drawn 
after blood culture bottles (if they are requested) 
and before non-additive tubes and clot activators 
(for serum), sodium heparin, lithium heparine, EDTA, 
acid-citrate-dextrose and oxalate/fluoride tubes (for 
whole blood). This so called “order of draw” has been 
established to prevent test result errors due to cross-
contamination from tube additives. 
However, Indevuyst et al (8) have found no 
significant influence at least for PT/INR and APTT 
values (measured in Sarstedt S-monovette tubes), 
if the citrate tube is obtained after a heparin, EDTA 
or a serum tube with clot activator. In a similar line 
of investigation, Salvagno et al (9) demonstrated 
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that chemistry parameters (potassium, sodium, 
calcium, magnesium, and Phosphorus) that are more 
likely to be biased by cross-contamination of ion-
chelating additives (EDTA and sodium citrate), are 
instead not affected by the order of draw of serum 
tubes (Venosafe, Terumo Europe). Both of these 
observations add to the evidence that the order of 
draw is no longer a requirement in coagulation testing.
Another issue in phlebotomy is the tube filling, 
which ideally is made up to the indicated mark. 
Though, underfilled tubes are a frequent finding (10, 
11) in routine coagulation testing, and laboratories 
should have procedures to deal with these kind of 
samples. CLSI recommends a minimum of 90% tube 
filling if APTT is to be tested (12), and recent evidence 
by Lippi et al (13) and Ver Elst et al (14) still support 
this recommendation. For PT and Fbg Lippi et al (15) 
found the minimum allowed threshold to be >61% 
and >71% filling respectively, while Ver Elst et al (14) 
determined a 73% and 63% filling threshold. In a 
similar study, Pretorius et al (16) recommended as safe 
in their setting an 80% fill volume for complete routine 
testing.  Different analytical platforms and tubes might 
explain the slight differences encountered, which puts 
in evidence the need for blood tubes validation by 
laboratories, as highlighted by Lima-Oliveira et al (17). 
For specialized coagulation tests, the available 
evidence adressing the influence of different blood 
volumes is scarce. In one study, Lippi et al (13) found 
that for activated protein C resistance (APCR) a blood 
volume as low as 67% has no clinical significance on 
test results, while for FVIII it is advisable to obtain at 
least 80%.
What’s new about sample stability – time to 
analysis?
With the consolidation era in laboratory medicine, 
more samples are collected in outside facilities, leading 
to possible delays in sample testing, so being aware 
of sample stability is key in coagulation testing. The 
issued recommendation by CLSI (H21-A5) on sample 
stability states that the assays should be completed, 
mostly within 4 hours of collection, except for PT (24h 
maximum), either on uncentrifuged or centrifuged 
samples kept at room temperature. Although this is a 
more conservative and safer approach, accumulated 
evidence in recent years suggests that proper 
measurements (without clinical significant difference) 
can still be made within a 24h frame not only for PT, 
but also for Fbg, D-dimers and thrombin time (TT) 
in samples transported/stored at room temperature 
and interestingly also at 4ºC (18-23). For APTT the 
evidence also suggests that storage can be extended, 
in this case up to 6-8 hours before testing (18-21, 
23-25), both at room temperature and 4ºC.
What’s new about testing interference in 
hemostasis?
Hemolysis interference is the leading cause of 
specimen rejection in coagulation laboratories (6), 
which is in agreement with CLSI recommendations 
(H21-A5) not to test samples with visible hemolysis. 
However, the evidence on the effects of spurious 
hemolysis on routine coagulation testing not only is 
scarce, but currently conflicting, because two recent 
studies (with updated measurement instruments) by 
Arora et al (26) and Lippi et al (27) concluded that 
the results obtained from hemolyzed samples for PT/
INR, APTT and Fbg were reliable and would not change 
the clinical interpretation when compared with non-
hemolyzed samples, which adds to the observations 
of Laga et al back in 2006 (28). D-dimer assays seem 
not to be affected by hemolysis even in the presence 
of high concentrations of cell-free haemoglobin (29, 
30)
From the current state of the art we can 
conclude that sample quality requirements for routine 
coagulation testing are evolving, and it seems essential 
that laboratories have updated and validated criteria 
on specimen acceptance/rejection, in order to avoid 
rejecting good specimens, reduce costs and delays, 
and improve patient safety.
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